Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7050 + Cetuximab in Platinum-Resistant SCCHN
NCT01332266Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2011
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of Golvatinib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Eisai Co., Ltd.. Started Sep 2011; status: completed.
02
Drugs
Golvatinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01332266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332266.